Open AccessClearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
Author(s) -
Taylor Ronald P.,
Lindorfer Margaret A.,
Atkinson John P.
Publication year - 2020
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1002/trc2.12067
Subject(s) - monoclonal antibody , antibody , amyloid (mycology) , beta (programming language) , complement (music) , complement receptor 1 , chemistry , complement system , immunology , cancer research , medicine , biochemistry , pathology , computer science , gene , phenotype , complementation , programming language
We propose use of bispecific monoclonal antibody (mAb) complexes bound to erythrocytes to redress the lack of efficacy of anti‐amyloid beta mAbs in Alzheimer's disease treatment. Our paradigm leverages erythrocyte complement receptor 1 to promote rapid and quantitative removal of amyloid beta from the circulation, and its subsequent removal from the brain as well.